Chikungunya

Global Chikungunya Pipeline Insight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 25, 2019
Health, Infectious diseases, Pharmaceutical, Medical specialties, Chikungunya, RTT, Drug pipeline, Medicine

The "Chikungunya - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chikungunya - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Chikungunya - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chikungunya development.
  • The report assesses the active Chikungunya pipeline products by developmental stage, product type, molecule type, and administration route.
  • clinical, pre-clinical and discovery stages for Chikungunya
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chikungunya

Enesi Pharma and Sementis Sign R&D Collaboration Focused on Needle-free Solid Dose Vaccines for Peanut Allergy and Chikungunya/Zika Infection

Retrieved on: 
Monday, November 5, 2018
Medicine, Vaccines, Health, Zika virus, Clinical medicine, Virology, RTT, Zika virus vaccine, Immunogenicity, Chikungunya

The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax technology.

Key Points: 
  • The collaboration is focused on the development and evaluation of solid dose versions of Sementis' lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma's ImplaVax technology.
  • Sementis' investigational peanut hypoallergy vaccine, based on its SCV vector platform, has completed proof-of-concept studies, providing compelling evidence that it offers the possibility of a permanent cure for peanut allergy.
  • Sementis has developed a novel vaccine platform that has demonstrated exciting results in proof-of-concept studies in allergy and infectious diseases.
  • Under the terms of the agreement, Enesi Pharma will formulate solid dose implants based on SCV vaccine provided by Sementis, and Sementis will undertake safety and immunogenicity testing, and preclinical development.

Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

Retrieved on: 
Tuesday, June 19, 2018
Hexapoda, Ecdysozoa, Medicine, Chikungunya, Malaria, Aedes aegypti, Dengue fever, Yellow fever, RTT, Mosquito, Oxitec, Anopheles

This collaboration will fund the development of a new self-limiting Friendly Anopheles mosquito strain designed to suppress wild malaria vector populations.

Key Points: 
  • This collaboration will fund the development of a new self-limiting Friendly Anopheles mosquito strain designed to suppress wild malaria vector populations.
  • "We've built a strong, proven biological engineering platform capable of developing self-limiting mosquito strains that can be used to combat specific disease-spreading species.
  • Oxitec will be using its new 2nd generation Friendly Mosquito technology to develop an Anopheles albimanus strain to address one of the most important vectors of malaria in the Americas.
  • Oxitec has developed a proven track record with its first self-limiting Friendly Mosquito, OX513A, which was designed to control Aedes aegypti mosquitoes.

FDA Grants PaxVax Fast Track Designation for its Chikungunya Vaccine

Retrieved on: 
Friday, May 4, 2018
Chikungunya, RTT, National Institute of Allergy and Infectious Diseases, Vaccines, Medicine, Julie Ledgerwood, Health, Influenza vaccines, Microbiology

REDWOOD CITY, Calif., May 4, 2018 /PRNewswire/ -- PaxVax, a leading independent specialty vaccine company, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its vaccine for the prevention of disease caused by the chikungunya virus.

Key Points: 
  • REDWOOD CITY, Calif., May 4, 2018 /PRNewswire/ -- PaxVax, a leading independent specialty vaccine company, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its vaccine for the prevention of disease caused by the chikungunya virus.
  • "This Fast Track designation is another positive step for the development of our chikungunya vaccine, in addition to our recent Phase 2b initial patient enrollment, and is a clear recognition of the serious unmet need," said Lisa Danzig, MD, Chief Medical Officer of PaxVax.
  • The vaccine was licensed from the National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH).
  • There are currently no FDA approved vaccines to prevent chikungunya and no specific treatments for the complications of the infection.

Atlanta Holds Top Spot on Orkin's 2018 Mosquito Cities List

Retrieved on: 
Monday, May 7, 2018
Hexapoda, Ecdysozoa, Medicine, Chikungunya, Insect control, Mosquito-borne disease, Mosquito, Aedes aegypti, Aedes, Culex, Aedes albopictus, Mosquito control

One of the best strategies for eliminating mosquito-borne diseases is to reduce populations of the mosquitos that spread them.

Key Points: 
  • One of the best strategies for eliminating mosquito-borne diseases is to reduce populations of the mosquitos that spread them.
  • Unlike other mosquito species, Aedes aegypti mosquitoes bite during the day and night.
  • Culex Mosquitoes: These mosquitoes are in every state and can carry and spread West Nile virus.
  • Reducing items that attract mosquitoes and actively working to prevent them from reproducing and moving inside the home are the best protection from mosquito bites.